OPRX

ANALYST NOTE: OPRX (OptimizeRx Corporation) Date: 2026-06-13 Current Price: $5.08

1. Structural Readiness

Conservative Entry: — (Awaiting confirmed breakout) Aggressive/Pre-Breakout Entry: — (Not actionable on setup alone; requires confirmation) Breakout Level: — (Not yet established) Current Price: $5.08 Extension: — (No extension calculated as no breakout has occurred) ATR Current: 7.6% (Very High)

Analysis of Setup:

2. Thesis Layer

Thesis Status: TACTICAL / SETUP-LED Macro Thesis: None named at this date.

This is a tactical, setup-led name. There is no named secular macro thesis driving the immediate conviction stack. The investment case must be judged strictly on the quality of the technical setup (once formed) and the underlying business fundamentals as reported by management. Do not invent a macro narrative; the conviction relies on the execution of the company's stated strategy and the structural readiness of the price action.

3. The Business

Company Overview: OptimizeRx Corporation is a digital healthcare technology firm that connects over two million healthcare providers (HCPs) and millions of patients through an intelligent technology platform embedded within a proprietary omnichannel network. The company operates in the Life Sciences and Digital Health industry.

Business Model & Operations: The company generates revenue by helping life sciences organizations engage and support their customers through combined HCP and Direct-to-Consumer (DTC) marketing strategies. Its core offerings include:

• Financial Messaging & Patient Support: Enabling HCPs to access sample vouchers, co-pay assistance, and patient support resources directly within Electronic Medical Records (EMR) or e-prescribing platforms.
• Mobile Health Messenger: A cloud-based platform offering interactive health messaging to bolster medication adherence.
• Consulting & Strategy: Guiding pharmaceutical manufacturers in eRx media strategies, including drug file integration and sales force education.
• DAAP (Digital Advertising & Analytics Platform): An AI-enabled solution that grew 60% in Q1 2026, connecting demand-side platforms (DSPs) controlling over 80% of digital promotional dollars to OptimizeRx's proprietary EHR network.

Financial Guidance & Performance (as of May 12, 2026): Management has provided specific forward-looking guidance recorded in the Q1 2026 earnings transcript:

• Revenue Expectation: $95 million to $100 million for the full year.
• EBITDA Guidance: Maintained at $21 million to $25 million (Adjusted).
• Gross Margin: Expected to be in the "high 60% range" for the full year.
• Seasonality: Revenue is expected to be weighted toward the second half of the year at a 40-60 split.
• Customer Concentration: The top 20 pharmaceutical manufacturers represent 52% of business in Q1 2026, with an average revenue per top 20 customer of approximately $2.8 million. The top five customers represented 47% of revenue in 2025.
• Channel Partners: 62% of revenue in 2025 was generated through two largest channel partners.

Strategic Shifts: Management is actively transitioning DAAP and MNT customers to a subscription-based model for data services to improve margin visibility and predictability. They aim to become a "Rule of 40" company (Revenue Growth + Adjusted EBITDA Margin ≥ 40%) within the next several years.

4. Archetype and Conviction

Archetype: Growth Leader Fit: The name fits the "Growth Leader" archetype due to the 60% growth in its AI-enabled DAAP solution, the strategic pivot toward high-margin subscription data services, and the management's explicit goal to achieve a "Rule of 40" status. The business model is shifting from transactional messaging to recurring, high-margin data services.

Valuation & Financial Spine:

• Forward Consensus EPS: FY1 (2026) $0.91642; FY2 (2027) $1.05598.
• Current Price Context: At $5.08, the stock trades at approximately 5.5x FY1 consensus EPS.
• ATR Context: The current ATR of 7.6% is "Very High." In the StoryStocks canon, high volatility (6-8%) is elevated and often precedes significant moves or indicates structural instability. This volatility complicates the definition of a clean "Conservative Entry" point, as the price may be oscillating within a wide range before a definitive breakout.

Conviction Stack:

• Thesis Strength: Moderate. The business fundamentals are strong (guidance met, margin expansion), but the lack of a named macro thesis limits the "secular" conviction weight.
• Evidence Quality: High. Management guidance is specific, and the transition to subscription models is clearly articulated.
• Structural Quality: Low/Incomplete. The setup is "Forming," meaning the structural breakout has not fired. The high ATR suggests the structure is still being tested.
• Setup Readiness: Partial. The setup is not actionable as a confirmed breakout. It requires a close above a defined resistance level to move from "Forming" to "Confirmed-Active."
• Rerating Potential: Moderate. If the company achieves its "Rule of 40" target and the DAAP growth sustains, the multiple could expand, but this is contingent on the setup firing.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Fundamental: Confirmation that the transition to the subscription model is accelerating faster than expected, or that the "Rule of 40" target is met sooner than the "next several years" timeline.
• Operational: Continued double-digit growth in the DAAP segment beyond the 60% Q1 figure.

What Would Invalidate the Case:

• Fundamental: A significant miss on the $95M-$100M revenue guidance or a compression of the high 60% gross margin target.
• Customer Concentration: A material loss of one of the top 20 customers, which currently represent 52% of business.

Gaps in Evidence:

• Debt Covenants: While the term loan maturity was extended to 2029, specific covenants or leverage ratios relative to the new guidance are not detailed in the provided evidence.
• Competitive Landscape: No specific data on competitive threats or market share shifts beyond the general industry trend toward digital spend.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management guidance of $95M-$100M revenue and $21M-$25M EBITDA; 60% growth in AI-enabled DAAP solution; strategic pivot to subscription model targeting Rule of 40. Key risks: Very high ATR (7.6%) indicating elevated volatility and structural noise; high customer concentration (top 20 represent 52% of business); setup remains "Forming" with no confirmed breakout. Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "Forming" state and elevated volatility. Expected path: Management expects revenue to be weighted 40-60% in the second half; the company aims to transition customers to subscription models to improve margin visibility. Expected horizon: 6 to 12 months for the setup to resolve into a confirmed breakout or invalidation.